vimarsana.com

Latest Breaking News On - Takeda yakuhin kogyo chart - Page 1 : vimarsana.com

U S FDA Approves Subcutaneous Administration of Takeda s ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn s Disease Seite 1

19.04.2024 - Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) . Seite 1

Timothy ritterSchool of medicineGi alliance researchDepartment of researchTakeda yakuhin kogyo chartAkeda yakuhin kogyo kursAkeda yakuhin kogyo aktie

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

27.03.2024 - Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano . Seite 1

Constantine saroukosOrdinary general meetingMilano furutaJapan pharma business unitTakeda yakuhin kogyo chartAkeda yakuhin kogyo kursAkeda yakuhin kogyo aktie

Takeda Receives Positive CHMP Opinion for HYQVIA as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

15.12.2023 - Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] .

United statesTakeda yakuhin kogyoTakeda pharmaceutical company limitedClinical programPeripheral nerve societyEuropean academy of neurology peripheral nerve societyExchange commissionEuropean medicines agencyEuropean academy of neurologyEuropean academyRecombinant human hyaluronidaseInflammatory neuropathy causeProduct characteristicsBaxalta innovations gmbhPharmaceutical company limitedAnnual report

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

26.10.2023 - Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2023 (six months ended September 30, 2023), updating reported and Core forecasts and reconfirming Management Guidance for Core change at CER. Takeda .

United statesTakeda yakuhin kogyoTakeda pharmaceutical company limitedInternational financial reporting standardsExchange commissionConstant exchange rateCosta saroukosManagement guidanceLaunch productsFree cash flowCore forecastsReconfirming managementAnnual reportScore revenueCore operatingCore net profit

vimarsana © 2020. All Rights Reserved.